Elizabeth Dudnik (E Dudnik)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 8

Top Venues

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Rabin Medical Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Rabin Medical Center Sep 01 2014

Israel

Attending pysician :: Thoracic Cancer Service, Davidoff Cancer Center

Publications

Oded Icht, Avi Leader, Erez Batat, Lilach Yosef, Tzippy Shochat, Daniel A Goldstein, Elizabeth Dudnik, Galia Spectre, Pia Raanani, Ariel Hammerman, Alona Zer
Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study. The oncologist (2023)
Ari Raphael, Elizabeth Dudnik, Dov Hershkovitz, Suyog Jain, Steven Olsen, Lior Soussan-Gutman, Taly Ben-Shitrit, Addie Dvir, Hovav Nechushtan, Nir Peled, Amir Onn, Abed Agbarya, null On Behalf Of The Israel Lung Cancer Group
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). Journal of clinical medicine 11 (9) (2022)
Mor Moskovitz, Elizabeth Dudnik, Sivan Shamai, Yakir Rotenberg, Noa Popovich-Hadari, Mira Wollner, Alona Zer, Maya Gottfried, Moshe Mishaeli, Shoshana Keren Rosenberg, Amir Onn, Ofer Merimsky, Damien Urban, Nir Peled, Natalie Maimon, Jair Bar
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data. The oncologist 27 (1) (2022)
Elizabeth Dudnik, Samuel Kareff, Mor Moskovitz, Chul Kim, Stephen V Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar, null null
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. Journal for immunotherapy of cancer 9 (2) (2022)
Nir Peled, Waleed Kian, Edna Inbar, Iris M Goldstein, Melanie Zemel, Ofer Rotem, Anna B Rozenblum, Hovav Nechushtan, Elizabeth Dudnik, Daniel Levin, Alona Zer, Shoshana Keren-Rosenberg, Shlomit Yust-Katz, Vered Fuchs, Areen A Remilah, Ilan Shelef, Laila C Roisman
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Neuro-oncology advances 4 (1) (2021)
Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar, null null
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. Oncoimmunology 10 (1) (2021)
Elizabeth Dudnik, Mor Moskovitz, Abed Agbarya, Teodor Gottfried, Tzippy Shochat, Damien Urban, Alona Zer, Ofer Rotem, Assaf Moore, Shlomit Yust, Nir Peled, Mira Wollner, Jair Bar, null null
Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidence. International journal of cancer 148 (5) (2020)
Elizabeth Dudnik, A Agbarya, R Grinberg, A Cyjon, J Bar, M Moskovitz, N Peled, null null
Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 22 (12) (2020)

Elizabeth Dudnik.css-eqlu8i{font-size:small;padding-left:4px;} (E Dudnik)

Publication Activity (10 Years)

Top Topics

Top Venues

Elizabeth Dudnik (E Dudnik)